234 related articles for article (PubMed ID: 19386081)
1. Effect of conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium on maximum tolerated dose and gastrointestinal symptoms following kidney transplantation.
Shehata M; Bhandari S; Venkat-Raman G; Moore R; D'Souza R; Riad H; Bakran A; Baker R; Needham C; Andrews C
Transpl Int; 2009 Aug; 22(8):821-30. PubMed ID: 19386081
[TBL] [Abstract][Full Text] [Related]
2. Gastrointestinal quality of life improvement of renal transplant recipients converted from mycophenolate mofetil to enteric-coated mycophenolate sodium drugs or agents: mycophenolate mofetil and enteric-coated mycophenolate sodium.
Ortega F; Sánchez-Fructuoso A; Cruzado JM; Gómez-Alamillo JC; Alarcón A; Pallardó L; Morales JM; Oliver J; Guinea G;
Transplantation; 2011 Aug; 92(4):426-32. PubMed ID: 21760569
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of tolerability and ability to increase immunosuppression in renal transplant patients converted from mycophenolate mofetil to enteric-coated mycophenolate sodium.
Bilodeau JF; Montambault P; Wolff JL; Lemire J; Masse M
Transplant Proc; 2009 Nov; 41(9):3683-9. PubMed ID: 19917367
[TBL] [Abstract][Full Text] [Related]
4. EC-MPS permits lower gastrointestinal symptom burden despite higher MPA exposure in patients with severe MMF-related gastrointestinal side-effects.
Sabbatini M; Capone D; Gallo R; Pisani A; Polichetti G; Tarantino G; Gentile A; Rotaia E; Federico S
Fundam Clin Pharmacol; 2009 Oct; 23(5):617-24. PubMed ID: 19656208
[TBL] [Abstract][Full Text] [Related]
5. Enteric-coated mycophenolate sodium: safe conversion from mycophenolate mofetil in maintenance renal transplant recipients.
Budde K; Glander P; Diekmann F; Dragun D; Waiser J; Fritsche L; Neumayer HH
Transplant Proc; 2004 Mar; 36(2 Suppl):524S-527S. PubMed ID: 15041401
[TBL] [Abstract][Full Text] [Related]
6. Enteric-coated mycophenolate sodium versus mycophenolate mofetil in renal transplant recipients experiencing gastrointestinal intolerance: a multicenter, double-blind, randomized study.
Langone AJ; Chan L; Bolin P; Cooper M
Transplantation; 2011 Feb; 91(4):470-8. PubMed ID: 21245794
[TBL] [Abstract][Full Text] [Related]
7. Safety assessment of the conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium in stable renal transplant recipients.
Massari P; Duro-Garcia V; Girón F; Hernández E; Juárez F; Castro C; Toledo M;
Transplant Proc; 2005 Mar; 37(2):916-9. PubMed ID: 15848574
[TBL] [Abstract][Full Text] [Related]
8. Conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium in maintenance renal transplant recipients receiving tacrolimus: clinical, pharmacokinetic, and pharmacodynamic outcomes.
Budde K; Glander P; Krämer BK; Fischer W; Hoffmann U; Bauer S; Grohmann J; Neumayer HH; Arns W
Transplantation; 2007 Feb; 83(4):417-24. PubMed ID: 17318074
[TBL] [Abstract][Full Text] [Related]
9. Superior efficacy of enteric-coated mycophenolate vs mycophenolate mofetil in de novo transplant recipients: pooled analysis.
Salvadori M; Bertoni E; Budde K; Holzer H; Civati G; Lien B; Arns W
Transplant Proc; 2010 May; 42(4):1325-8. PubMed ID: 20534293
[TBL] [Abstract][Full Text] [Related]
10. Conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium in renal transplant recipients with gastrointestinal tract disorders.
Darji P; Vijayaraghavan R; Thiagarajan CM; Sharma RK; Subbarao B; Pishardy R; Dakshinamurthy KV; Vijaykumar R; Abraham G; Bhaskar S; Agarwal L; Shah B; Abraham A; John M; Sampathkumar K; Das T; Umesh L; Sundar S; Ballal H; Jasuja S; Saxena S; Saha TK
Transplant Proc; 2008 Sep; 40(7):2262-7. PubMed ID: 18790208
[TBL] [Abstract][Full Text] [Related]
11. Better mycophenolic acid 12-hour trough level after enteric-coated mycophenolate sodium in patients with gastrointestinal intolerance to mycophenolate mofetil.
Sánchez Fructuoso A; Calvo N; Moreno MA; Giorgi M; Conesa J; Barrientos A
Transplant Proc; 2007 Sep; 39(7):2194-6. PubMed ID: 17889135
[TBL] [Abstract][Full Text] [Related]
12. A prospective analysis of the effects of enteric-coated mycophenolate sodium and mycophenolate mofetil co-medicated with a proton pump inhibitor in kidney transplant recipients at a single institute in China.
Xu L; Cai M; Shi BY; Li ZL; Li X; Jin HL
Transplant Proc; 2014 Jun; 46(5):1362-5. PubMed ID: 24935300
[TBL] [Abstract][Full Text] [Related]
13. Conversion to enteric-coated mycophenolate sodium from various doses of mycophenolate mofetil: results of a prospective international multicenter trial in maintenance renal transplant patients receiving cyclosporine.
Nashan B; Suwelack B; Ivens K; Arns W; Lhotta K; Bourbigot B; Budde K; Fischer W; Pietruck F;
Transplant Proc; 2006 Nov; 38(9):2856-9. PubMed ID: 17112848
[TBL] [Abstract][Full Text] [Related]
14. Successful conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium (myfortic) in liver transplant patients with gastrointestinal side effects.
Robaeys G; Cassiman D; Verslype C; Monbaliu D; Aerts R; Pirenne J; Nevens F
Transplant Proc; 2009 Mar; 41(2):610-3. PubMed ID: 19328938
[TBL] [Abstract][Full Text] [Related]
15. Long-term safety and efficacy after conversion of maintenance renal transplant recipients from mycophenolate mofetil (MMF) to enteric-coated mycophenolate sodium (EC-MPA, myfortic).
Budde K; Knoll G; Curtis J; Chan L; Pohanka E; Gentil M; Seifu Y; Marrast AC; Neumayer HH;
Clin Nephrol; 2006 Aug; 66(2):103-11. PubMed ID: 16939066
[TBL] [Abstract][Full Text] [Related]
16. Comparing outcomes associated with dose manipulations of enteric-coated mycophenolate sodium versus mycophenolate mofetil in renal transplant recipients.
Cooper M; Deering KL; Slakey DP; Harshaw Q; Arcona S; McCann EL; Rasetto FA; Florman SS
Transplantation; 2009 Aug; 88(4):514-20. PubMed ID: 19696634
[TBL] [Abstract][Full Text] [Related]
17. Improvement in gastrointestinal and health-related quality of life outcomes after conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium in liver transplant recipients.
Sterneck M; Settmacher U; Ganten T; Sarrazin C; Speidel N; Broering D; Heyne N; Paulus E; Mertens M; Fischer L
Transplant Proc; 2014; 46(1):234-40. PubMed ID: 24507058
[TBL] [Abstract][Full Text] [Related]
18. Enteric-coated mycophenolate sodium reduces gastrointestinal symptoms in renal transplant patients.
Burg M; Säemann MD; Wieser C; Kramer S; Fischer W; Lhotta K
Transplant Proc; 2009 Dec; 41(10):4159-64. PubMed ID: 20005359
[TBL] [Abstract][Full Text] [Related]
19. Improved gastrointestinal symptoms and quality of life after conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium in renal transplant patients receiving tacrolimus.
Hwang HS; Hyoung BJ; Kim S; Oh HY; Kim YS; Kim JK; Kim YH; Kim YL; Kim CD; Shin GT; Yang CW
J Korean Med Sci; 2010 Dec; 25(12):1759-65. PubMed ID: 21165291
[TBL] [Abstract][Full Text] [Related]
20. Long-term dosing patterns of enteric-coated mycophenolate sodium or mycophenolate mofetil with tacrolimus after renal transplantation.
Langone A; Shihab F; Pankewycz O; Doria C; Wiland A; McCague K; Chan L
Clin Transplant; 2014 Sep; 28(9):961-7. PubMed ID: 24893821
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]